Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

Discovery of PG545: a highly potent and simultaneous inhibitor of angiogenesis, tumor growth, and metastasis.

Ferro V, Liu L, Johnstone KD, Wimmer N, Karoli T, Handley P, Rowley J, Dredge K, Li CP, Hammond E, Davis K, Sarimaa L, Harenberg J, Bytheway I.

J Med Chem. 2012 Apr 26;55(8):3804-13. doi: 10.1021/jm201708h. Epub 2012 Apr 13.

PMID:
22458531
2.

Synthesis and biological evaluation of polysulfated oligosaccharide glycosides as inhibitors of angiogenesis and tumor growth.

Johnstone KD, Karoli T, Liu L, Dredge K, Copeman E, Li CP, Davis K, Hammond E, Bytheway I, Kostewicz E, Chiu FC, Shackleford DM, Charman SA, Charman WN, Harenberg J, Gonda TJ, Ferro V.

J Med Chem. 2010 Feb 25;53(4):1686-99. doi: 10.1021/jm901449m.

PMID:
20128596
3.

The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy.

Dredge K, Hammond E, Davis K, Li CP, Liu L, Johnstone K, Handley P, Wimmer N, Gonda TJ, Gautam A, Ferro V, Bytheway I.

Invest New Drugs. 2010 Jun;28(3):276-83. doi: 10.1007/s10637-009-9245-5. Epub 2009 Apr 9.

PMID:
19357810
4.

PI-88 and novel heparan sulfate mimetics inhibit angiogenesis.

Ferro V, Dredge K, Liu L, Hammond E, Bytheway I, Li C, Johnstone K, Karoli T, Davis K, Copeman E, Gautam A.

Semin Thromb Hemost. 2007 Jul;33(5):557-68. Review.

PMID:
17629854
5.

Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate.

Vlodavsky I, Ilan N, Naggi A, Casu B.

Curr Pharm Des. 2007;13(20):2057-73. Review.

PMID:
17627539
6.

PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models.

Dredge K, Hammond E, Handley P, Gonda TJ, Smith MT, Vincent C, Brandt R, Ferro V, Bytheway I.

Br J Cancer. 2011 Feb 15;104(4):635-42. doi: 10.1038/bjc.2011.11. Epub 2011 Feb 1.

7.
8.

CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.

Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.

Cancer Res. 2003 Sep 15;63(18):5978-91. Erratum in: Cancer Res. 2003 Nov 1;63(21):7543.

9.

PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancer.

Ostapoff KT, Awasthi N, Cenik BK, Hinz S, Dredge K, Schwarz RE, Brekken RA.

Mol Cancer Ther. 2013 Jul;12(7):1190-201. doi: 10.1158/1535-7163.MCT-12-1123. Epub 2013 May 21.

10.

Oligomannurarate sulfate, a novel heparanase inhibitor simultaneously targeting basic fibroblast growth factor, combats tumor angiogenesis and metastasis.

Zhao H, Liu H, Chen Y, Xin X, Li J, Hou Y, Zhang Z, Zhang X, Xie C, Geng M, Ding J.

Cancer Res. 2006 Sep 1;66(17):8779-87.

11.
12.

The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth.

Ruggeri BA, Robinson C, Angeles T, Wilkinson J 4th, Clapper ML.

Clin Cancer Res. 2002 Jan;8(1):267-74.

13.

Endothelial heparan sulfate 6-O-sulfation levels regulate angiogenic responses of endothelial cells to fibroblast growth factor 2 and vascular endothelial growth factor.

Ferreras C, Rushton G, Cole CL, Babur M, Telfer BA, van Kuppevelt TH, Gardiner JM, Williams KJ, Jayson GC, Avizienyte E.

J Biol Chem. 2012 Oct 19;287(43):36132-46. doi: 10.1074/jbc.M112.384875. Epub 2012 Aug 27.

14.

The anti-angiogenic and anti-tumor activity of synthetic phenylpropenone derivatives is mediated through the inhibition of receptor tyrosine kinases.

Lee JS, Kang Y, Kim JT, Thapa D, Lee ES, Kim JA.

Eur J Pharmacol. 2012 Feb 29;677(1-3):22-30. doi: 10.1016/j.ejphar.2011.12.012. Epub 2011 Dec 20.

PMID:
22200628
15.

Extracellular matrix-resident growth factors and enzymes: possible involvement in tumor metastasis and angiogenesis.

Vlodavsky I, Korner G, Ishai-Michaeli R, Bashkin P, Bar-Shavit R, Fuks Z.

Cancer Metastasis Rev. 1990 Nov;9(3):203-26. Review.

PMID:
1705486
16.

Use of sulfated linked cyclitols as heparan sulfate mimetics to probe the heparin/heparan sulfate binding specificity of proteins.

Freeman C, Liu L, Banwell MG, Brown KJ, Bezos A, Ferro V, Parish CR.

J Biol Chem. 2005 Mar 11;280(10):8842-9. Epub 2005 Jan 4.

17.

Heparanase activation induces epidermal hyperplasia, angiogenesis, lymphangiogenesis and wrinkles.

Iriyama S, Matsunaga Y, Amano S.

Exp Dermatol. 2010 Nov;19(11):965-72. doi: 10.1111/j.1600-0625.2009.01027.x.

PMID:
20100191
18.

Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.

Ferguson D, Rodriguez LE, Palma JP, Refici M, Jarvis K, O'Connor J, Sullivan GM, Frost D, Marsh K, Bauch J, Zhang H, Lin NH, Rosenberg S, Sham HL, Joseph IB.

Clin Cancer Res. 2005 Apr 15;11(8):3045-54.

19.

SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.

Cao ZX, Zheng RL, Lin HJ, Luo SD, Zhou Y, Xu YZ, Zeng XX, Wang Z, Zhou LN, Mao YQ, Yang L, Wei YQ, Yu LT, Yang SY, Zhao YL.

Cell Physiol Biochem. 2011;27(5):565-74. doi: 10.1159/000329978. Epub 2011 Jun 15.

20.

Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.

Starzec A, Vassy R, Martin A, Lecouvey M, Di Benedetto M, Crépin M, Perret GY.

Life Sci. 2006 Nov 17;79(25):2370-81. Epub 2006 Aug 16.

PMID:
16959272

Supplemental Content

Support Center